{"id":861799,"date":"2025-06-18T11:24:01","date_gmt":"2025-06-18T15:24:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/"},"modified":"2025-06-18T11:24:01","modified_gmt":"2025-06-18T15:24:01","slug":"outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/","title":{"rendered":"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event"},"content":{"rendered":"

\nLive webcast on Wednesday, June 25th at 12:00 PM ET
\n<\/h2>\n
\n

ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc.<\/a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event<\/a> on Wednesday, June 25, 2025 at 12:00 PM ET.<\/p>\n

As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP \u2013 Head of Europe, will discuss the Company\u2019s commercial strategy, upcoming milestones and current activities. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.<\/p>\n

A live video webcast<\/a> will be available on the Events<\/a> page under the Investors<\/a> section of the Company\u2019s website (outlooktherapeutics.com<\/a>). A webcast replay will be available two hours following the live event and will be accessible for 90 days.<\/p>\n

About Outlook Therapeutics, Inc.<\/strong><\/p>\n

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA\u2122 (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA\u2122 (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.<\/p>\n

In the United States, ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010\/LYTENAVA\u2122, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.<\/p>\n

\n Investor Inquiries:<\/strong>\n <\/p>\n

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Live webcast on Wednesday, June 25th at 12:00 PM ET ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET. As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP \u2013 Head of Europe, will discuss the Company\u2019s commercial strategy, upcoming milestones and current activities. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions … <\/p>\n

Continue reading “Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-861799","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOutlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Live webcast on Wednesday, June 25th at 12:00 PM ET ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET. As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP \u2013 Head of Europe, will discuss the Company\u2019s commercial strategy, upcoming milestones and current activities. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions … Continue reading "Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-18T15:24:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event\",\"datePublished\":\"2025-06-18T15:24:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/\"},\"wordCount\":317,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/\",\"name\":\"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI=\",\"datePublished\":\"2025-06-18T15:24:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/","og_locale":"en_US","og_type":"article","og_title":"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - Market Newsdesk","og_description":"Live webcast on Wednesday, June 25th at 12:00 PM ET ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET. As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP \u2013 Head of Europe, will discuss the Company\u2019s commercial strategy, upcoming milestones and current activities. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions … Continue reading \"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-18T15:24:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event","datePublished":"2025-06-18T15:24:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/"},"wordCount":317,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/","name":"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI=","datePublished":"2025-06-18T15:24:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDQ3MyM2OTk2NTI1IzIwMjg4MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-in-a-virtual-investor-lunch-break-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/861799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=861799"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/861799\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=861799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=861799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=861799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}